<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209325</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-072</org_study_id>
    <secondary_id>AMC-072</secondary_id>
    <secondary_id>U01CA121947</secondary_id>
    <secondary_id>CDR0000685816</secondary_id>
    <nct_id>NCT01209325</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males</brief_title>
  <official_title>AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Emmes Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIDS and Cancer Specimen Resource</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Malignancy Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective
      immune response to prevent viral infection.

      PURPOSE: This phase II trial is studying how well vaccine therapy works in preventing human
      papillomavirus (HPV) infection in young HIV-positive male patients who have sex with males.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the protective effect of the HPV-6, -11, -16, -18 vaccine in preventing
           penile/scrotal condyloma and HPV-6, -11, -16, -18- associated perianal/anal disease in
           HIV-positive males who have sex with males (MSM) age 13-26 years by comparing the
           incidence of these lesions among those naïve to the relevant HPV type(s) at baseline to
           those who are not naïve at baseline.

        -  To determine the protective effect of the HPV-6, -11, -16, -18 vaccine in preventing
           persistent anogenital infection with HPV-6, -11, -16, or 18 in HIV-positive MSM age
           13-26 years by comparing the incidence of persistent infection among those naïve to the
           relevant HPV type(s) at baseline to those who are not naïve at baseline.

        -  To determine the protective effect of the HPV-6, -11, -16, -18 vaccine in preventing
           anogenital lesions associated with HPV 6,-11,-16, -18 and persistent infection with
           these types, in HIV-positive MSM age 13-26 years by comparing the incidence of lesions
           and persistent infection among those naïve to the relevant types at baseline to incident
           lesions and infection among MSM naïve to these HPV types who participated in the Merck
           020 protocol and who received placebo as part of the protocol.

      Secondary

        -  To define the safety of the HPV-6, -11, -16, -18 vaccine in HIV-positive MSM age 13-26
           years.

        -  To evaluate the levels and persistence of HPV 6, 11, 16 and 18 Ab titers after the
           vaccination series among subjects who are seropositive and seronegative at baseline.

        -  To examine whether the protective effect and antibody titers vary as a function of the
           following at the time of initial vaccination: subject age, HAART treatment status, HIV
           viral load, CD4 + T-cell count, and nadir CD4 level.

      Tertiary

        -  To quantify anogenital HPV DNA viral load prior to and after receipt of the quadrivalent
           HPV vaccine.

        -  To identify and quantify HPV types in the oral cavity of HIV-positive MSM prior to and
           after receipt of the quadrivalent HPV vaccine.

        -  To identify HPV strain variants among HIV-positive participants prior to and after
           receipt of the quadrivalent HPV vaccine.

        -  Assess the prevalence and incidence of urinary and gonorrhea and Chlamydia trachomatis
           infection at baseline and their relationship with prevalent and incident anogenital HPV
           infection and anal condyloma or AIN.

        -  To characterize young men's risk perceptions, sexual behaviors, and STI diagnosis after
           HPV vaccination.

      OUTLINE: This is a multicenter study.

      Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant
      vaccine intramuscularly on day 1 and in weeks 8 and 24.

      Blood and tissue samples may be collected periodically for laboratory studies.

      After completion of study treatment, patients are followed up for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2011</start_date>
  <completion_date type="Actual">December 12, 2017</completion_date>
  <primary_completion_date type="Actual">December 12, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6 DNA</measure>
    <time_frame>Post Month 7 through Month 24</time_frame>
    <description>Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 6 positive DNA in participants without HPV-6 related AIN at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 11 DNA</measure>
    <time_frame>Post Month 7 through Month 24</time_frame>
    <description>Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 11 positive DNA in participants without HPV-11 related AIN at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 16 DNA</measure>
    <time_frame>Post Month 7 through Month 24</time_frame>
    <description>Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 16 positive DNA in participants without HPV-16 related AIN at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 18 DNA</measure>
    <time_frame>Post Month 7 through Month 24</time_frame>
    <description>Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 18 positive DNA in participants without HPV-18 related AIN at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Persistent Anogenital Infection With HPV 6 DNA</measure>
    <time_frame>Post Month 7 through Month 24</time_frame>
    <description>Incident events are defined as having HPV 6 positive PCR results at 2 or more consecutive visits in those who were DNA negative for HPV 6. Persistence was defined based on being persistent in the same anatomical site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Persistent Anogenital Infection With HPV 11 DNA</measure>
    <time_frame>Post Month 7 through Month 24</time_frame>
    <description>Incident events are defined as having positive PCR results with HPV 11 at 2 or more consecutive visits in those who were DNA negative for HPV 11 at baseline. Persistence was defined based on being persistent in the same anatomical site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Persistent Anogenital Infection With HPV 16 DNA</measure>
    <time_frame>Post Month 7 through Month 24</time_frame>
    <description>Incident events are defined as having positive PCR results with HPV 16 at 2 or more consecutive visits in those who were DNA negative for HPV 16 at baseline. Persistence was defined based on being persistent in the same anatomical site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Persistent Anogenital Infection With HPV 18 DNA</measure>
    <time_frame>Post Month 7 through Month 24</time_frame>
    <description>Incident events are defined as having positive PCR results with HPV 18 at 2 or more consecutive visits in those who were DNA negative for HPV 18. Persistence was defined based on being persistent in the same anatomical site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of HGAIN Associated With HPV 6</measure>
    <time_frame>Post month 7 through month 24</time_frame>
    <description>Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 6 positive DNA in participants without HPV 6 related HGAIN at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of HGAIN Associated With HPV 11</measure>
    <time_frame>Post month 7 through month 24</time_frame>
    <description>Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 11 positive DNA in participants without HPV 11 related HGAIN at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of HGAIN Associated With HPV 16</measure>
    <time_frame>Post month 7 through month 24</time_frame>
    <description>Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 16 positive DNA in participants without HPV 16 related HGAIN at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of HGAIN Associated With HPV 18</measure>
    <time_frame>Post month 7 through month 24</time_frame>
    <description>Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 18 positive DNA in participants without HPV 18 related HGAIN at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Penile/Scrotal Condyloma in HPV 6 Naive and Prior Exposed Participants</measure>
    <time_frame>Post month 7 through month 24</time_frame>
    <description>Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Penile/Scrotal Condyloma in HPV 11 Naive and Prior Exposed Participants</measure>
    <time_frame>Post month 7 through month 24</time_frame>
    <description>Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Penile/Scrotal Condyloma in HPV 16 Naive and Prior Exposed Participants</measure>
    <time_frame>Post month 7 through month 24</time_frame>
    <description>Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Penile/Scrotal Condyloma in HPV 18 Naive and Prior Exposed Participants</measure>
    <time_frame>Post month 7 through month 24</time_frame>
    <description>Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Grade ≥ 3 Adverse Events (AEs) That Were Possibly, Probably, or Definitely Related to the Vaccine</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Number of participants who experienced grade 3 and higher AEs that were possibly, probably or definitely related to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers for HPV 6</measure>
    <time_frame>Baseline through month 24</time_frame>
    <description>Geometric mean concentration of antibodies for HPV 6 at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers for HPV 11</measure>
    <time_frame>Baseline through month 24</time_frame>
    <description>Geometric mean concentration of antibodies for HPV 11 at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers for HPV 16</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Geometric mean concentration of antibodies for HPV 16 at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers for HPV 18</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Geometric mean concentration of antibodies for HPV 18 at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers for HPV 6 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level</measure>
    <time_frame>at 7 and 24 Months</time_frame>
    <description>Geometric mean concentration of antibodies for HPV 6 at 7 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers for HPV 11 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level</measure>
    <time_frame>at 7 and 24 Months</time_frame>
    <description>Geometric mean concentration of antibodies for HPV 11 at 7 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers for HPV 16 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level</measure>
    <time_frame>at 7 and 24 Months</time_frame>
    <description>Geometric mean concentration of antibodies for HPV 16 at 7 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers for HPV 18 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level</measure>
    <time_frame>at 7 and 24 Months</time_frame>
    <description>Geometric mean concentration of antibodies for HPV 18 at 7 and 24 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Anal Cancer</condition>
  <condition>Nonneoplastic Condition</condition>
  <condition>Penile Cancer</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine</intervention_name>
    <arm_group_label>Vaccination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Men with a history of at least one male sexual partner

               -  &quot;Men&quot; is defined as those documented &quot;male&quot; at birth (including male-to-female
                  transgendered persons)

          -  HIV-1 infection as documented by any federally approved, licensed HIV test performed
             in conjunction with screening (ELISA, western blot, or other approved test)

               -  Alternatively, this documentation may include a record that another physician has
                  documented that the patient has HIV based on prior ELISA and western blot, or
                  other approved diagnostic tests

          -  Meets one of the following sets of criteria:

               -  Patients receiving antiretroviral therapy:

                    -  Receipt of antiretroviral therapy for at least 3 months prior to entry

                    -  No change in antiretroviral therapy within 30 days prior to entry

               -  Patients not receiving antiretroviral therapy:

                    -  CD4-cell count ≥ 350 cells/mm³ within 90 days prior to study entry

                    -  No plans to start antiretroviral therapy prior to Week 28

          -  Normal anal cytological result, LSIL/condyloma, or ASCUS result within 90 days prior
             to entry, and no HGAIN on biopsy

               -  No current or history of anal or peri-anal carcinoma

               -  No anal cytological result of HSIL, atypical squamous cells suggestive of HSIL
                  (ASC-H), or suggestive of invasive carcinoma at screening; or history of these
                  results

          -  No presence of penile or scrotal condyloma, LGAIN (condyloma or AIN 1), HGAIN (e.g.,
             AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3), or invasive carcinoma
             at pre-entry on biopsy

          -  No history of HGAIN

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance score ≥ 70 within 45 days prior to entry

          -  Absolute neutrophil count (ANC) &gt; 750 cells/mm^3

          -  Hemoglobin ≥ 9.0 g/dL

          -  Platelet count ≥ 100,000/mm^3

          -  AST (SGOT), ALT (SGPT) ≤ 3 times upper limit of normal (ULN)

          -  Total or conjugated (direct) bilirubin ≤ 2.5 times ULN within 45 days before study
             entry, with the exception of isolated hyperbilirubinemia that is considered due to
             atazanavir

          -  Calculated creatinine clearance ≥ 60 mL/min

          -  No hemophilia

          -  No active drug or alcohol use or dependence that, in the opinion of the site
             Investigator, would interfere with adherence to study requirements

          -  No serious illness requiring systemic treatment and/or hospitalization within 45 days
             prior to entry

          -  No serious medical or psychiatric illness that, in the opinion of the site
             Investigator, will interfere with the ability of the subject to give informed consent
             or adhere to the protocol

          -  No allergy to yeast or any of the components of Gardasil

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior splenectomy

          -  No prior receipt of Gardasil or other HPV vaccine

          -  No use of any systemic antineoplastic or immunomodulatory treatment, systemic
             corticosteroids for greater than 14 days, investigational vaccines, interleukins,
             interferons, growth factors, or IVIG within 45 days prior to study entry

          -  No expected use of any systemic antineoplastic or immunomodulatory treatment, systemic
             corticosteroids used for greater than 14 days, investigational vaccines, interleukins,
             interferons, growth factors, or IVIG during study followup

               -  No patients with hepatitis C who expect to initiate treatment for hepatitis C
                  (e.g., interferons) during this trial

          -  Not currently receiving anticoagulation therapy other than acetylsalicylic acid
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Palefsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Clinical AIDS Research and Education (CARE) Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center at UC Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John H. Stroger, Jr. Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-9985</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruth M. Rothstein Core Center at Cook County Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fenway Community Health</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Cancer Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser Surgery Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude's Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Street Health Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dan L. Duncan Cancer Center at Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico Comprehensive Cancer Center</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 24, 2010</study_first_submitted>
  <study_first_submitted_qc>September 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <results_first_submitted>April 29, 2020</results_first_submitted>
  <results_first_submitted_qc>May 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 27, 2020</results_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>human papilloma virus infection</keyword>
  <keyword>anal cancer</keyword>
  <keyword>penile cancer</keyword>
  <keyword>HIV infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Penile Neoplasms</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 2, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT01209325/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vaccination</title>
          <description>Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
laboratory biomarker analysis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received First Vaccine Injection</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Second Vaccine Injection</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Third Vaccine Infjection</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Returned After Week 28</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal after starting therapy</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal prior to therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incarceration</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible participants who received at least one dose of vaccine.</population>
      <group_list>
        <group group_id="B1">
          <title>Vaccination</title>
          <description>Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
laboratory biomarker analysis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.5" lower_limit="18.1" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6 DNA</title>
        <description>Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 6 positive DNA in participants without HPV-6 related AIN at baseline.</description>
        <time_frame>Post Month 7 through Month 24</time_frame>
        <population>Eligible participants without prevalent HPV 6 related AIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 6</title>
            <description>HPV 6 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 6</title>
            <description>HPV 6 positive based on serum at visit 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6 DNA</title>
          <description>Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 6 positive DNA in participants without HPV-6 related AIN at baseline.</description>
          <population>Eligible participants without prevalent HPV 6 related AIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
          <units>Events per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.112</p_value>
            <p_value_desc>Two-sided p-value</p_value_desc>
            <method>Exact poisson test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This study's Naive to HPV 6 group was compared to the per-protocol Merck 020 historical placebo group naive to HPV 6 (NCT00090285), 0.0 events per 100 person years (PY) versus 3.4 events per 100 PY, respectively.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.447</p_value>
            <p_value_desc>One-sided test</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 11 DNA</title>
        <description>Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 11 positive DNA in participants without HPV-11 related AIN at baseline.</description>
        <time_frame>Post Month 7 through Month 24</time_frame>
        <population>Eligible participants without prevalent HPV 11 related AIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 11</title>
            <description>HPV 11 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 11</title>
            <description>HPV 11 positive based on serum at visit 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 11 DNA</title>
          <description>Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 11 positive DNA in participants without HPV-11 related AIN at baseline.</description>
          <population>Eligible participants without prevalent HPV 11 related AIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
          <units>Events per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.224</p_value>
            <p_value_desc>Two-sided p-value.</p_value_desc>
            <method>Exact poisson test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This study's Naive to HPV 11 group was compared to the per-protocol Merck 020 historical placebo group naive to HPV 11 (NCT00090285), 0.0 events per 100 person years (PY) versus 2.0 events per 100 PY, respectively.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>One-sided p-value.</non_inferiority_desc>
            <p_value>0.361</p_value>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 16 DNA</title>
        <description>Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 16 positive DNA in participants without HPV-16 related AIN at baseline.</description>
        <time_frame>Post Month 7 through Month 24</time_frame>
        <population>Eligible participants without prevalent HPV 16 related AIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 16</title>
            <description>HPV 16 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 16</title>
            <description>HPV 16 positive based on serum at visit 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 16 DNA</title>
          <description>Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 16 positive DNA in participants without HPV-16 related AIN at baseline.</description>
          <population>Eligible participants without prevalent HPV 16 related AIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
          <units>Events per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.079</p_value>
            <p_value_desc>Two-sided p-value.</p_value_desc>
            <method>Exact poisson test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This study's Naive to HPV 16 group was compared to the per-protocol Merck 020 historical placebo group naive to HPV 16 (NCT00090285), 0.0 events per 100 person years (PY) versus 1.8 events per 100 PY, respectively.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.350</p_value>
            <p_value_desc>One-sided p-value.</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 18 DNA</title>
        <description>Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 18 positive DNA in participants without HPV-18 related AIN at baseline.</description>
        <time_frame>Post Month 7 through Month 24</time_frame>
        <population>Eligible participants without prevalent HPV 18 related AIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 18</title>
            <description>HPV 18 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 18</title>
            <description>HPV 18 positive based on serum at visit 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 18 DNA</title>
          <description>Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 18 positive DNA in participants without HPV-18 related AIN at baseline.</description>
          <population>Eligible participants without prevalent HPV 18 related AIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
          <units>Events per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.162</p_value>
            <method>Exact poisson test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This study's Naive to HPV 18 group was compared to the Merck 020 per-protocol historical placebo group naive to HPV 18 (NCT00090285), 0.0 events per 100 person years (PY) versus 1.0 events per 100 PY, respectively.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.490</p_value>
            <p_value_desc>One-sided p-value</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Persistent Anogenital Infection With HPV 6 DNA</title>
        <description>Incident events are defined as having HPV 6 positive PCR results at 2 or more consecutive visits in those who were DNA negative for HPV 6. Persistence was defined based on being persistent in the same anatomical site.</description>
        <time_frame>Post Month 7 through Month 24</time_frame>
        <population>All eligible participants who were HPV 6 DNA negative at baseline and received at least one vaccination and returned after month 7 with evaluable PCR tests at two consecutive visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 6</title>
            <description>HPV 6 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure HPV 6</title>
            <description>HPV 6 positive based on serum at visit 0 from any anatomical site.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Persistent Anogenital Infection With HPV 6 DNA</title>
          <description>Incident events are defined as having HPV 6 positive PCR results at 2 or more consecutive visits in those who were DNA negative for HPV 6. Persistence was defined based on being persistent in the same anatomical site.</description>
          <population>All eligible participants who were HPV 6 DNA negative at baseline and received at least one vaccination and returned after month 7 with evaluable PCR tests at two consecutive visits.</population>
          <units>events per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.671</p_value>
            <p_value_desc>Two-sided p-value is comparing naive and prior exposure groups for HPV 6.</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This study's Naive to HPV 6 group was compared to the per-protocol Merck 020 historical placebo group naive to HPV 6 (NCT00090285), 1.8 events per 100 person years (PY) versus 4.5 events per 100 PY, respectively.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.312</p_value>
            <p_value_desc>One-sided p-value.</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Persistent Anogenital Infection With HPV 11 DNA</title>
        <description>Incident events are defined as having positive PCR results with HPV 11 at 2 or more consecutive visits in those who were DNA negative for HPV 11 at baseline. Persistence was defined based on being persistent in the same anatomical site.</description>
        <time_frame>Post Month 7 through Month 24</time_frame>
        <population>All eligible participants who were HPV 11 DNA negative at baseline and received at least one vaccination and returned after month 7 with evaluable PCR tests at two consecutive visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 11</title>
            <description>HPV 11 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 11</title>
            <description>HPV 11 positive based on serum at visit 0 from any anatomical site.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Persistent Anogenital Infection With HPV 11 DNA</title>
          <description>Incident events are defined as having positive PCR results with HPV 11 at 2 or more consecutive visits in those who were DNA negative for HPV 11 at baseline. Persistence was defined based on being persistent in the same anatomical site.</description>
          <population>All eligible participants who were HPV 11 DNA negative at baseline and received at least one vaccination and returned after month 7 with evaluable PCR tests at two consecutive visits.</population>
          <units>events per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <p_value_desc>Two-sided p-value.</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This study's Naive to HPV 11 group was compared to the per-protocol Merck 020 historical placebo group naive to HPV 11 (NCT00090285), 0.0 events per 100 person years (PY) versus 1.7 events per 100 PY, respectively.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.209</p_value>
            <p_value_desc>One-sided p-value.</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Persistent Anogenital Infection With HPV 16 DNA</title>
        <description>Incident events are defined as having positive PCR results with HPV 16 at 2 or more consecutive visits in those who were DNA negative for HPV 16 at baseline. Persistence was defined based on being persistent in the same anatomical site.</description>
        <time_frame>Post Month 7 through Month 24</time_frame>
        <population>All eligible participants who were HPV 16 DNA negative at baseline and received at least one vaccination and returned after month 7 with evaluable PCR tests at two consecutive visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 16</title>
            <description>HPV 16 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 16</title>
            <description>HPV 16 positive based on serum at visit 0 from any anatomical site.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Persistent Anogenital Infection With HPV 16 DNA</title>
          <description>Incident events are defined as having positive PCR results with HPV 16 at 2 or more consecutive visits in those who were DNA negative for HPV 16 at baseline. Persistence was defined based on being persistent in the same anatomical site.</description>
          <population>All eligible participants who were HPV 16 DNA negative at baseline and received at least one vaccination and returned after month 7 with evaluable PCR tests at two consecutive visits.</population>
          <units>events per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.386</p_value>
            <p_value_desc>Two-sided p-value.</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This study's Naive to HPV 16 group was compared to the per-protocol Merck 020 historical placebo group naive to HPV 16 (NCT00090285), 2.9 events per 100 person years (PY) versus 4.9 events per 100 PY, respectively.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.305</p_value>
            <p_value_desc>One-sided test</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Persistent Anogenital Infection With HPV 18 DNA</title>
        <description>Incident events are defined as having positive PCR results with HPV 18 at 2 or more consecutive visits in those who were DNA negative for HPV 18. Persistence was defined based on being persistent in the same anatomical site.</description>
        <time_frame>Post Month 7 through Month 24</time_frame>
        <population>All eligible participants who were HPV 18 DNA negative at baseline and received at least one vaccination and returned after month 7 with evaluable PCR tests at two consecutive visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 18</title>
            <description>HPV 18 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 18</title>
            <description>HPV 18 positive based on serum at visit 0 from any anatomical site.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Persistent Anogenital Infection With HPV 18 DNA</title>
          <description>Incident events are defined as having positive PCR results with HPV 18 at 2 or more consecutive visits in those who were DNA negative for HPV 18. Persistence was defined based on being persistent in the same anatomical site.</description>
          <population>All eligible participants who were HPV 18 DNA negative at baseline and received at least one vaccination and returned after month 7 with evaluable PCR tests at two consecutive visits.</population>
          <units>events per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.622</p_value>
            <p_value_desc>Two-sided p-value.</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This study's Naive to HPV 18 group was compared to the per-protocol Merck 020 historical placebo group naive to HPV 18 (NCT00090285), 0.7 events per 100 person years (PY) versus 2.7 events per 100 PY, respectively.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.150</p_value>
            <p_value_desc>One-sided p-value.</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of HGAIN Associated With HPV 6</title>
        <description>Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 6 positive DNA in participants without HPV 6 related HGAIN at baseline.</description>
        <time_frame>Post month 7 through month 24</time_frame>
        <population>Eligible participants without prevalent HPV 6 related HGAIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 6</title>
            <description>HPV 6 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 6</title>
            <description>HPV 6 positive based on serum at visit 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of HGAIN Associated With HPV 6</title>
          <description>Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 6 positive DNA in participants without HPV 6 related HGAIN at baseline.</description>
          <population>Eligible participants without prevalent HPV 6 related HGAIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
          <units>per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.064</p_value>
            <p_value_desc>Two-sided p-value.</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of HGAIN Associated With HPV 11</title>
        <description>Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 11 positive DNA in participants without HPV 11 related HGAIN at baseline.</description>
        <time_frame>Post month 7 through month 24</time_frame>
        <population>Eligible participants without prevalent HPV 11 related HGAIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 11</title>
            <description>HPV 11 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 11</title>
            <description>HPV 11 positive based on serum at visit 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of HGAIN Associated With HPV 11</title>
          <description>Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 11 positive DNA in participants without HPV 11 related HGAIN at baseline.</description>
          <population>Eligible participants without prevalent HPV 11 related HGAIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
          <units>per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.745</p_value>
            <p_value_desc>Two-sided test.</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of HGAIN Associated With HPV 16</title>
        <description>Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 16 positive DNA in participants without HPV 16 related HGAIN at baseline.</description>
        <time_frame>Post month 7 through month 24</time_frame>
        <population>Eligible participants without prevalent HPV 16 related HGAIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 16</title>
            <description>HPV 16 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 16</title>
            <description>HPV 16 positive based on serum at visit 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of HGAIN Associated With HPV 16</title>
          <description>Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 16 positive DNA in participants without HPV 16 related HGAIN at baseline.</description>
          <population>Eligible participants without prevalent HPV 16 related HGAIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
          <units>per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of HGAIN Associated With HPV 18</title>
        <description>Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 18 positive DNA in participants without HPV 18 related HGAIN at baseline.</description>
        <time_frame>Post month 7 through month 24</time_frame>
        <population>Eligible participants without prevalent HPV 18 related HGAIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 18</title>
            <description>HPV 18 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 18</title>
            <description>HPV 18 positive based on serum at visit 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of HGAIN Associated With HPV 18</title>
          <description>Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 18 positive DNA in participants without HPV 18 related HGAIN at baseline.</description>
          <population>Eligible participants without prevalent HPV 18 related HGAIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.</population>
          <units>per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.166</p_value>
            <p_value_desc>Two-sided p-value.</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Penile/Scrotal Condyloma in HPV 6 Naive and Prior Exposed Participants</title>
        <description>Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline.</description>
        <time_frame>Post month 7 through month 24</time_frame>
        <population>Eligible participants without penile/scrotal condyloma at baseline who received at least one vaccination and returned after month 7 with evaluable clinical assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 6</title>
            <description>HPV 6 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 6</title>
            <description>HPV 6 positive based on serum at visit 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Penile/Scrotal Condyloma in HPV 6 Naive and Prior Exposed Participants</title>
          <description>Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline.</description>
          <population>Eligible participants without penile/scrotal condyloma at baseline who received at least one vaccination and returned after month 7 with evaluable clinical assessments.</population>
          <units>per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.789</p_value>
            <p_value_desc>Two-sided p-value.</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Penile/Scrotal Condyloma in HPV 11 Naive and Prior Exposed Participants</title>
        <description>Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline.</description>
        <time_frame>Post month 7 through month 24</time_frame>
        <population>Eligible participants without penile/scrotal condyloma at baseline who received at least one vaccination and returned after month 7 with evaluable clinical assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 11</title>
            <description>HPV 11 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 11</title>
            <description>HPV 11 positive based on serum at visit 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Penile/Scrotal Condyloma in HPV 11 Naive and Prior Exposed Participants</title>
          <description>Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline.</description>
          <population>Eligible participants without penile/scrotal condyloma at baseline who received at least one vaccination and returned after month 7 with evaluable clinical assessments.</population>
          <units>per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.809</p_value>
            <p_value_desc>Two-sided p-value.</p_value_desc>
            <method>0.809</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Penile/Scrotal Condyloma in HPV 16 Naive and Prior Exposed Participants</title>
        <description>Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline.</description>
        <time_frame>Post month 7 through month 24</time_frame>
        <population>Eligible participants without penile/scrotal condyloma at baseline who received at least one vaccination and returned after month 7 with evaluable clinical assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 16</title>
            <description>HPV 16 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 16</title>
            <description>HPV 16 positive based on serum at visit 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Penile/Scrotal Condyloma in HPV 16 Naive and Prior Exposed Participants</title>
          <description>Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline.</description>
          <population>Eligible participants without penile/scrotal condyloma at baseline who received at least one vaccination and returned after month 7 with evaluable clinical assessments.</population>
          <units>per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.422</p_value>
            <p_value_desc>Two-sided p-value.</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Penile/Scrotal Condyloma in HPV 18 Naive and Prior Exposed Participants</title>
        <description>Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline.</description>
        <time_frame>Post month 7 through month 24</time_frame>
        <population>Eligible participants without penile/scrotal condyloma at baseline who received at least one vaccination and returned after month 7 with evaluable clinical assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive to HPV 18</title>
            <description>HPV 18 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.</description>
          </group>
          <group group_id="O2">
            <title>Prior Exposure to HPV 18</title>
            <description>HPV 18 positive based on serum at visit 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Penile/Scrotal Condyloma in HPV 18 Naive and Prior Exposed Participants</title>
          <description>Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline.</description>
          <population>Eligible participants without penile/scrotal condyloma at baseline who received at least one vaccination and returned after month 7 with evaluable clinical assessments.</population>
          <units>per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.423</p_value>
            <p_value_desc>Two-sided p-value.</p_value_desc>
            <method>Exact Poisson calculation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Grade ≥ 3 Adverse Events (AEs) That Were Possibly, Probably, or Definitely Related to the Vaccine</title>
        <description>Number of participants who experienced grade 3 and higher AEs that were possibly, probably or definitely related to the vaccine.</description>
        <time_frame>Through Month 24</time_frame>
        <population>The safety population included eligible participants who received at least one vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccination</title>
            <description>Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
laboratory biomarker analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Grade ≥ 3 Adverse Events (AEs) That Were Possibly, Probably, or Definitely Related to the Vaccine</title>
          <description>Number of participants who experienced grade 3 and higher AEs that were possibly, probably or definitely related to the vaccine.</description>
          <population>The safety population included eligible participants who received at least one vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers for HPV 6</title>
        <description>Geometric mean concentration of antibodies for HPV 6 at each visit</description>
        <time_frame>Baseline through month 24</time_frame>
        <population>Eligible participants who received at least one vaccination with evaluable serum assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>HPV 6 Sero-negative at Baseline</title>
            <description>Sero-negative for HPV 6 at baseline.</description>
          </group>
          <group group_id="O2">
            <title>HPV 6 Sero-positive at Baseline</title>
            <description>Sero-positive for HPV 6 at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers for HPV 6</title>
          <description>Geometric mean concentration of antibodies for HPV 6 at each visit</description>
          <population>Eligible participants who received at least one vaccination with evaluable serum assessments.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="81.7" lower_limit="64.5" upper_limit="851.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.3" lower_limit="236.4" upper_limit="386.6"/>
                    <measurement group_id="O2" value="637.8" lower_limit="477.6" upper_limit="851.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.8" lower_limit="83.6" upper_limit="149.4"/>
                    <measurement group_id="O2" value="420.9" lower_limit="318.2" upper_limit="556.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7" lower_limit="55.8" upper_limit="113.9"/>
                    <measurement group_id="O2" value="335.3" lower_limit="262.8" upper_limit="428.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="48.5" upper_limit="112.0"/>
                    <measurement group_id="O2" value="356.6" lower_limit="272.4" upper_limit="466.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers for HPV 11</title>
        <description>Geometric mean concentration of antibodies for HPV 11 at each visit</description>
        <time_frame>Baseline through month 24</time_frame>
        <population>Eligible participants who received at least one vaccination with evaluable serum assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>HPV 11 Sero-negative at Baseline</title>
            <description>Sero-negative for HPV 11 at baseline.</description>
          </group>
          <group group_id="O2">
            <title>HPV 11 Sero-positive at Baseline</title>
            <description>Sero-positive for HPV 11 at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers for HPV 11</title>
          <description>Geometric mean concentration of antibodies for HPV 11 at each visit</description>
          <population>Eligible participants who received at least one vaccination with evaluable serum assessments.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="42.7" lower_limit="30.1" upper_limit="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="452.4" lower_limit="378.1" upper_limit="541.4"/>
                    <measurement group_id="O2" value="976.2" lower_limit="757.5" upper_limit="1258.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.0" lower_limit="102.7" upper_limit="169.8"/>
                    <measurement group_id="O2" value="493.7" lower_limit="355.2" upper_limit="686.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6" lower_limit="67.2" upper_limit="119.4"/>
                    <measurement group_id="O2" value="373.2" lower_limit="262.1" upper_limit="531.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4" lower_limit="62.1" upper_limit="114.9"/>
                    <measurement group_id="O2" value="300.2" lower_limit="205.8" upper_limit="438.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers for HPV 16</title>
        <description>Geometric mean concentration of antibodies for HPV 16 at each visit</description>
        <time_frame>Baseline through 24 months</time_frame>
        <population>Eligible participants who received at least one vaccination with evaluable serum assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>HPV 16 Sero-negative at Baseline</title>
            <description>Sero-negative for HPV 16 at baseline.</description>
          </group>
          <group group_id="O2">
            <title>HPV 16 Sero-positive at Baseline</title>
            <description>Sero-positive for HPV 16 at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers for HPV 16</title>
          <description>Geometric mean concentration of antibodies for HPV 16 at each visit</description>
          <population>Eligible participants who received at least one vaccination with evaluable serum assessments.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="66.6" lower_limit="46.7" upper_limit="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1535.6" lower_limit="1272.5" upper_limit="1853.1"/>
                    <measurement group_id="O2" value="2947.8" lower_limit="2249.0" upper_limit="3863.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="451.6" lower_limit="352.5" upper_limit="578.5"/>
                    <measurement group_id="O2" value="1436.6" lower_limit="1095.2" upper_limit="1884.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309.5" lower_limit="237.6" upper_limit="403.1"/>
                    <measurement group_id="O2" value="1242.9" lower_limit="892.2" upper_limit="1731.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272.4" lower_limit="195.5" upper_limit="379.6"/>
                    <measurement group_id="O2" value="1079.5" lower_limit="771.8" upper_limit="1510.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers for HPV 18</title>
        <description>Geometric mean concentration of antibodies for HPV 18 at each visit</description>
        <time_frame>Baseline through 24 months</time_frame>
        <population>Eligible participants who received at least one vaccination with evaluable serum assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>HPV 18 Sero-negative at Baseline</title>
            <description>Sero-negative for HPV 18 at baseline.</description>
          </group>
          <group group_id="O2">
            <title>HPV 18 Sero-positive at Baseline</title>
            <description>Sero-positive for HPV 18 at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers for HPV 18</title>
          <description>Geometric mean concentration of antibodies for HPV 18 at each visit</description>
          <population>Eligible participants who received at least one vaccination with evaluable serum assessments.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="41.3" lower_limit="28.1" upper_limit="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.2" lower_limit="232.8" upper_limit="371.8"/>
                    <measurement group_id="O2" value="482.2" lower_limit="351.9" upper_limit="660.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" lower_limit="48.7" upper_limit="81.6"/>
                    <measurement group_id="O2" value="214.6" lower_limit="141.0" upper_limit="326.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" lower_limit="29.7" upper_limit="51.7"/>
                    <measurement group_id="O2" value="244.3" lower_limit="158.0" upper_limit="377.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" lower_limit="28.7" upper_limit="52.8"/>
                    <measurement group_id="O2" value="161.9" lower_limit="103.3" upper_limit="253.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers for HPV 6 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level</title>
        <description>Geometric mean concentration of antibodies for HPV 6 at 7 and 24 months</description>
        <time_frame>at 7 and 24 Months</time_frame>
        <population>Eligible participants who received at least one vaccination and who were sero-negative for HPV 6 at baseline with evaluable serum assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Month 7 Visit</title>
            <description>Month 7 visit after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Month 24 Visit</title>
            <description>Month 24 visit after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers for HPV 6 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level</title>
          <description>Geometric mean concentration of antibodies for HPV 6 at 7 and 24 months</description>
          <population>Eligible participants who received at least one vaccination and who were sero-negative for HPV 6 at baseline with evaluable serum assessments.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age&lt;24 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319" lower_limit="227" upper_limit="451"/>
                    <measurement group_id="O2" value="71" lower_limit="42" upper_limit="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age&gt;=24 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304" lower_limit="200" upper_limit="463"/>
                    <measurement group_id="O2" value="77" lower_limit="37" upper_limit="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline HIV viral load &lt;=75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324" lower_limit="244" upper_limit="431"/>
                    <measurement group_id="O2" value="81" lower_limit="53" upper_limit="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline HIV viral load &gt;75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250" lower_limit="118" upper_limit="528"/>
                    <measurement group_id="O2" value="45" lower_limit="8" upper_limit="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline CD4 &lt;=500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341" lower_limit="178" upper_limit="657"/>
                    <measurement group_id="O2" value="97" lower_limit="44" upper_limit="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline CD4 &gt;500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302" lower_limit="229" upper_limit="399"/>
                    <measurement group_id="O2" value="66" lower_limit="39" upper_limit="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nadir CD4 &lt;=350</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361" lower_limit="222" upper_limit="584"/>
                    <measurement group_id="O2" value="77" lower_limit="38" upper_limit="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nadir CD4&gt;350</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300" lower_limit="214" upper_limit="421"/>
                    <measurement group_id="O2" value="75" lower_limit="42" upper_limit="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers for HPV 11 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level</title>
        <description>Geometric mean concentration of antibodies for HPV 11 at 7 and 24 months</description>
        <time_frame>at 7 and 24 Months</time_frame>
        <population>Eligible participants who received at least one vaccination and who were sero-negative for HPV 11 at baseline with evaluable serum assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Month 7 Visit</title>
            <description>Month 7 visit after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Month 24 Visit</title>
            <description>Month 24 visit after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers for HPV 11 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level</title>
          <description>Geometric mean concentration of antibodies for HPV 11 at 7 and 24 months</description>
          <population>Eligible participants who received at least one vaccination and who were sero-negative for HPV 11 at baseline with evaluable serum assessments.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age&lt;24 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="434" lower_limit="336" upper_limit="561"/>
                    <measurement group_id="O2" value="71" lower_limit="49" upper_limit="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age&gt;=24 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="482" lower_limit="361" upper_limit="645"/>
                    <measurement group_id="O2" value="104" lower_limit="61" upper_limit="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline HIV viral load &lt;=75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="473" lower_limit="385" upper_limit="583"/>
                    <measurement group_id="O2" value="86" lower_limit="63" upper_limit="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline HIV viral load &gt;75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365" lower_limit="226" upper_limit="587"/>
                    <measurement group_id="O2" value="75" lower_limit="21" upper_limit="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline CD4 &lt;=500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="475" lower_limit="354" upper_limit="638"/>
                    <measurement group_id="O2" value="98" lower_limit="59" upper_limit="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline CD4 &gt;500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445" lower_limit="347" upper_limit="571"/>
                    <measurement group_id="O2" value="78" lower_limit="53" upper_limit="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nadir CD4 &lt;=350</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="469" lower_limit="351" upper_limit="626"/>
                    <measurement group_id="O2" value="87" lower_limit="57" upper_limit="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nadir CD4&gt;350</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="452" lower_limit="344" upper_limit="594"/>
                    <measurement group_id="O2" value="82" lower_limit="50" upper_limit="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers for HPV 16 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level</title>
        <description>Geometric mean concentration of antibodies for HPV 16 at 7 and 24 months</description>
        <time_frame>at 7 and 24 Months</time_frame>
        <population>Eligible participants who received at least one vaccination and who were sero-negative for HPV 16 at baseline with evaluable serum assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Month 7 Visit</title>
            <description>Month 7 visit after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Month 24 Visit</title>
            <description>Month 24 visit after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers for HPV 16 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level</title>
          <description>Geometric mean concentration of antibodies for HPV 16 at 7 and 24 months</description>
          <population>Eligible participants who received at least one vaccination and who were sero-negative for HPV 16 at baseline with evaluable serum assessments.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age&lt;24 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1572" lower_limit="1239" upper_limit="1995"/>
                    <measurement group_id="O2" value="268" lower_limit="185" upper_limit="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age&gt;=24 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1467" lower_limit="1013" upper_limit="2126"/>
                    <measurement group_id="O2" value="272" lower_limit="131" upper_limit="566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline HIV viral load &lt;=75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1630" lower_limit="1328" upper_limit="2002"/>
                    <measurement group_id="O2" value="282" lower_limit="200" upper_limit="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline HIV viral load &gt;75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="914" lower_limit="441" upper_limit="1894"/>
                    <measurement group_id="O2" value="201" lower_limit="51" upper_limit="795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline CD4 &lt;=500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1556" lower_limit="1123" upper_limit="2156"/>
                    <measurement group_id="O2" value="359" lower_limit="218" upper_limit="590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline CD4 &gt;500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1522" lower_limit="1178" upper_limit="1967"/>
                    <measurement group_id="O2" value="229" lower_limit="145" upper_limit="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nadir CD4 &lt;=350</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1390" lower_limit="1040" upper_limit="1857"/>
                    <measurement group_id="O2" value="245" lower_limit="151" upper_limit="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nadir CD4&gt;350</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1752" lower_limit="1303" upper_limit="2354"/>
                    <measurement group_id="O2" value="313" lower_limit="186" upper_limit="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers for HPV 18 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level</title>
        <description>Geometric mean concentration of antibodies for HPV 18 at 7 and 24 months</description>
        <time_frame>at 7 and 24 Months</time_frame>
        <population>Eligible participants who received at least one vaccination and who were sero-negative for HPV 18 at baseline with evaluable serum assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Month 7 Visit</title>
            <description>Month 7 visit after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Month 24 Visit</title>
            <description>Month 24 visit after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers for HPV 18 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level</title>
          <description>Geometric mean concentration of antibodies for HPV 18 at 7 and 24 months</description>
          <population>Eligible participants who received at least one vaccination and who were sero-negative for HPV 18 at baseline with evaluable serum assessments.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age&lt;24 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310" lower_limit="230" upper_limit="418"/>
                    <measurement group_id="O2" value="37" lower_limit="25" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age&gt;=24 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281" lower_limit="180" upper_limit="437"/>
                    <measurement group_id="O2" value="42" lower_limit="26" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline HIV viral load &lt;=75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333" lower_limit="258" upper_limit="431"/>
                    <measurement group_id="O2" value="42" lower_limit="30" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline HIV viral load &gt;75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123" lower_limit="57" upper_limit="267"/>
                    <measurement group_id="O2" value="25" lower_limit="7" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline CD4 &lt;=500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327" lower_limit="209" upper_limit="511"/>
                    <measurement group_id="O2" value="45" lower_limit="26" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline CD4 &gt;500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282" lower_limit="208" upper_limit="381"/>
                    <measurement group_id="O2" value="36" lower_limit="25" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nadir CD4 &lt;=350</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338" lower_limit="240" upper_limit="476"/>
                    <measurement group_id="O2" value="42" lower_limit="29" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nadir CD4&gt;350</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268" lower_limit="185" upper_limit="387"/>
                    <measurement group_id="O2" value="36" lower_limit="21" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment through 2 years after the first injection of Gardasil.</time_frame>
      <desc>All adverse events (AEs), regardless of severity, and whether or not ascribed to the study vaccine administration, were recorded. All Grade ≥ 2 laboratory values (except for CD4 cell counts) were recorded as AEs. After Week 32, only SAEs and AEs or symptoms &gt; grade 3 or symptoms that were possibly, probably, or definitely related to the study vaccine were recorded. Subjects who were withdrawn from the study due to AEs were to be followed by the Investigator until the outcome was determined.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vaccination</title>
          <description>Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
laboratory biomarker analysis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Gum infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders - other, specify</sub_title>
                <description>Homicidal ideation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorder - other, specify</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joel M. Palefsky</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-476-1574</phone>
      <email>jpalefsky@medicine.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

